All News Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
6.6 ^DKK	+0.61%		+11.86%	-9.09%

Feb. 29	Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

A short business update	Apr. 18	AQ
Minutes from the Annual General Meeting in Cessatech A/S	Mar. 27	AQ
Annual General Meeting - 27 March 2024	Mar. 11	AQ
Cessatech A/S publishes Annual Report for the fiscal year 2023	Feb. 29	AQ
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2	Jan. 30	AQ
LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024	Jan. 23	AQ
CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2	Jan. 22	AQ
CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2	Jan. 12	AQ
CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD	Jan. 11	AQ
Q&A session related topline data Study 0205	Jan. 04	AQ
Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001	Dec. 22	PU
Third Quarter Report Q3-2023	Nov. 16	AQ
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children	23-10-25	AQ
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	23-10-25	CI
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001	23-09-21	AQ
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	23-09-21	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	23-09-12	MT
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children	23-09-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Cessatech A/S

Equities

CESSA

DK0061411964

All News

Filters